Grants Management Branch, Bureau of Health Professions, Health Resources and Services Administration, Parklawn Building, Room 8C–26, 5600 Fishers Lane, Rockville, Maryland 20857.

For applicants who are unable to access application materials electronically, a hard copy will be provided be contacting the HRSA Grants Application Center. The Center may be contacted by: Telephone Number: 1–888–300–HRSA; FAX Number: 301–309–0579; Email Address: HRSA.GAC@IX.NETCOM.COM.

Completed applications should be returned to: Grants Management Officer (CFDA#), HRSA Grants Application

Center, 40 West Gude Drive, Suite 100, Rockville, Maryland 20850.

Paperwork Reduction Act

The standard application form PHS 6025–1, HRSA Competing Training Grant Application, General Instructions and supplement for these grant programs have been approved by the Office of Management and Budget under the Paperwork Reduction Act. The OMB Clearance Number is 0915–0060.

Deadline Date

The deadline dates for receipt of applications for each of these programs are shown in Table 1. Applications will be considered to be "on time" if they are either:

- (1) *Received on or before* the established deadline date, or
- (2) Sent on or before the established deadline date and received in time for orderly processing. (Applicants should request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

Late applications not accepted for processing will be returned to the applicant. In addition, applications which exceed the page limitation and/or do not follow format instructions will not be accepted for processing and will be returned to the applicant.

TABLE 1

PHS Section No., Title, CFDA No., Regulation	Type of assistance	Period of support (years)	Deadline date
746(a)(1), Basic/Core AHEC, 93.824, 42 CFR part 57 subpart MM746(a)(3), State Supported Model AHEC, 93.107	Cooperative Agreement	3 3	3/21/97 3/21/97

These programs are not subject to the provisions of Executive Order 12372, Intergovernmental Review of Federal Programs (as implemented through 45 CFR part 100) or the Public Health System Reporting Requirements.

Dated: January 28, 1997.

Ciro V. Sumaya, *Administrator*.

[FR Doc. 97-2682 Filed 2-3-97; 8:45 am]

BILLING CODE 4160-15-P

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the following National Heart, Lung, and Blood Institute Special Emphasis Panel.

The meeting will be open to the public to provide concept review of proposed contract or grant solicitations.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contact Person listed below in advance of the meeting.

Name of Panel: Heart and Vascular Diseases Research Opportunities. Dates of Meeting: March 26, 1997. Time of Meeting: 8:30 a.m. Place of Meeting: NIH, Building 31, C Wing, Conference Room 6, 31 Center Drive, Bethesda Maryland 20892.

Agenda: Discussion of Future Initiatives with Emphasis on Critical Health Care Needs

and Research Opportunities Related to Heart and Vascular Diseases.

Contact Person: Frank Altieri, Ph.D., NHLBI/DHVD, Two Rockledge Center, 6701 Rockledge Drive, Rm. 9166, MSC 7940, Bethesda, Maryland 20892, (301) 435–0494.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: January 29, 1997.

Paula N. Hayes,

Acting Committee management Officer, NIH. [FR Doc. 97–2725 Filed 2–3–97; 8:45 am]
BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meetings:

Name of SEP: Conjugated Pneumococcal Vaccine in Sickle Cell Disease.

Date: February 25, 1997.

Time: 8:00 a.m.

Place: Hyatt Regency Hotel, One Metro Center, Bethesda, Maryland 20814.

Contact Person: Ivan Baines, Ph.D., Two Rockledge Center, Room 7184, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0277.

Purpose/Agenda: To review and evaluate grant applications.

This notice is being published less than fifteen days prior to this meeting due to the

urgent need to meet timing limitations imposed by the grant review and funding cycle.

Name of SEP: Collaborative Study on the Genetics of Asthma.

Date: March 18, 1997.

Time: 8:00 a.m.

Place: Crystal City Marriott, 1999 Jefferson Davis Highway, Arlington, Virginia 22202.

Contact Person: C. James Scheirer, Ph.D, Two Rockledge Center, Room 7220, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0266.

Purpose/Agenda: To review and evaluate grant applications.

These meetings will be closed in accordance with the provisions set forth in Sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: January 29, 1997.

Paula N. Haves

Acting Committee Management Officer, NIH. [FR Doc. 97–2727 Filed 2–3–97; 8:45 am]
BILLING CODE 4140–01–M